ClinVar Miner

Submissions for variant NC_000023.10:g.(31838201_31854834)_(31950345_31986455)dup

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV002282863 SCV002570749 pathogenic Qualitative or quantitative defects of dystrophin 2022-07-06 criteria provided, single submitter clinical testing Variant summary: The variant identified by MLPA or other technology involves the duplication of exons 46-49 in the DMD gene. A presumed nomenclature of c.(6614+1_6615-1)_(7200+1_7201-1)dup has been designated for the purposes of this classification. It has been assumed that this is a tandem duplication in direct orientation (Richardson_GIM_2018, Newman_AJHG_2015). Although exact breakpoints of this duplication are not known, it is expected to result in a frameshift in the DMD gene, a known mechanism of disease. The variant was absent in 16117 control chromosomes (gnomAD, Structural Variants dataset). Duplication of exons 46-49 has been reported in the literature in individuals affected with Dystrophinopathies (e.g. Cunniff_2009, Polavarapu_2019). These data indicate that the variant is likely to be associated with disease. A ClinVar submitter (evaluation after 2014) cites the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.